Alexander Habermeier, co-founder of Guideways: “At Guideways, our mission is easy: get 10 instances extra life-changing improvements to sufferers, sooner and even safer. We’re thrilled to have efficiently closed our pre-Seed funding spherical. This funding will speed up the event of our groundbreaking AI platform and empower MedTech innovators to ship their life-saving new applied sciences to sufferers months, and even years, sooner.”

In context: This pre-Seed funding Guideways aligns with a broader 2025 development throughout Europe the place AI and automation are being utilized to regulatory and compliance challenges in MedTech.

In April 2025, REMATIQ (Berlin) raised €5.4 million to advance its AI-native platform for automated product compliance, highlighting investor confidence in instruments that streamline regulatory workflows. Earlier within the yr, Mulder secured €597k in pre-Seed funding to develop a medical-device traceability platform.

Whereas each REMATIQ and Mulder function in adjoining compliance and traceability niches, Guideways stands out for its give attention to agentic AI constructed particularly for regulatory approval processes – initially concentrating on U.S. FDA pathways earlier than increasing to European MDR frameworks.

Douwe Jippes, Co-founder and Managing accomplice at Wholesome.Capital: “The crew at Guideways has a deep, private understanding of the issue they’re fixing. They assist corporations to convey improvements to market sooner and extra efficiently by considerably lowering the approval time and prices, basically altering how medical gadgets are delivered to market. This makes healthcare innovation extra accessible and environment friendly, which completely aligns with our mission at Wholesome.Capital to make healthcare inexpensive and accessible.”

Based in 2024, Guideways develops AI brokers that “lower via regulatory approval, compliance, and reimbursement complexity” for MedTech innovators.

With greater than 37 years of mixed MedTech expertise, the founding crew has seen first-hand how regulatory hurdles derail promising improvements. Guideways’ platform goals to automate probably the most time-consuming components of compliance via a collection of specialized AI brokers, centered initially on the U.S. FDA approval course of:

• FDA Sherpa: guides groups from an idea description to an in depth approval technique, figuring out the proper classification, pathway, necessities, and requirements.

• FDA Reviewer: performs in-depth checks of regulatory submissions, reviewing tons of of paperwork for compliance and suggesting fixes.

• FDA Researcher: allows natural-language exploration of a data base of greater than 150,000 reference paperwork, combining info intelligently to reply complicated queries.

Saskia ten Siethoff, QA/RA Specialist, Flux Robotics added: “Utilizing Guideways’ FDA Sherpa helped us shortly outline our supposed use and map out the fitting FDA pathway for our next-generation vascular surgical procedure robotic. It not solely saved time but in addition defined the reasoning behind its suggestions; one thing that basically constructed confidence to navigate complicated laws.”